Yuezong Bai

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Zhijie Wang, Jianchun Duan, Shangli Cai et al. · JAMA Oncology · 2019 · 491 citations · Full text

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Wu‐tong Ju, Ronghui Xia, Dongwang Zhu et al. · Nature Communications · 2022 · 112 citations · Full text

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Wenwen Zhang, Shuang Tong, Bingyang Hu et al. · Journal for ImmunoTherapy of Cancer · 2023 · 109 citations · Full text

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

Dongsheng Yue, Weiran Liu, Chen Chen et al. · Translational Lung Cancer Research · 2022 · 100 citations · Full text

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer

Yuezong Bai, Tong Xie, Zhenghang Wang et al. · Journal for ImmunoTherapy of Cancer · 2022 · 97 citations · Full text